<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378935</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-367-1168</org_study_id>
    <nct_id>NCT02378935</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection</brief_title>
  <official_title>A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of GS-9857 plus sofosbuvir
      (SOF)/velpatasvir (VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with
      chronic genotype 1 hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA change from baseline</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with virologic failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>On treatment virologic failure is defined as:
HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment, confirmed with 2 consecutive values or last available on-treatment measurement with no subsequent follow-up values (ie, breakthrough)
&gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values or last available on-treatment measurement with no subsequent follow-up values (ie, rebound)
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse is defined as:
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 8 weeks (treatment naive (TN), without cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL+RBV 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 8 weeks (failed prior treatment, without cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 12 weeks (failed prior treatment, without cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 8 weeks (failed prior treatment, with cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 12 weeks (failed prior treatment, with cirrhosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/VEL 12 wk (GS-US-338-1121)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9857 + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9857</intervention_name>
    <description>GS-9857 100 mg tablet administered orally once daily with food</description>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL+RBV 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk (GS-US-338-1121)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/VEL</intervention_name>
    <description>SOF/VEL (400/100 mg) FDC tablet administered orally once daily with food</description>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 6 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL+RBV 8 wk, TN, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, without cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 8 wk, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk, with cirrhosis</arm_group_label>
    <arm_group_label>GS-9857+SOF/VEL 12 wk (GS-US-338-1121)</arm_group_label>
    <other_name>GS-7997/GS-5816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>GS-9857+SOF/VEL+RBV 8 wk, TN, with cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with chronic HCV infection

          -  HCV RNA ≥10^4 IU/mL at screening

          -  HCV genotype 1

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two contraception methods if female of childbearing potential or sexually
             active male

        Exclusion Criteria:

          -  Pregnant or nursing female

          -  Current or prior history of hepatic decompensation

          -  Hepatocellular carcinoma (HCC) or other clinically significant malignancy

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Yang, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital Liver Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Center of Gastroenterology, P.A.</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hep C/Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis Gastroenterology &amp; Hepatology, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Deconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital and Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Care Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore/Long Island Jewish PRIME</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists, PA</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health Systems</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Center for Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Gastrointestinal Specialists, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 22, 2015</lastchanged_date>
  <firstreceived_date>February 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
